Cholic acid
|
Basic information |
| Metabolite name | Cholic acid |
 | HMDB0000619 |
 |
C00695 |
 |
221493 |
| Synonyms | Cholate |
| No. of studies | 36 |
|
Basic information |
| Metabolite name | Cholic acid |
| HMDB0000619 |
|
C00695 |
|
221493 |
| Synonyms | Cholate |
| No. of studies | 36 |
|
Relationship between Cholic acid and depression (count: 36) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M007 | Type1 | CRS group vs. control group | Plasma | Wistar rat | Up |
| Study M048 | Type1 | CVS group vs. control group | Serum | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Serum | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Serum | Wistar rat | Up |
| Study M074 | Type1 | sCSDS group vs. control group | Faece | C57BL/6JJmsSlc mouse | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M095 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1022 | Type1 | CUS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M1022 | Type2 | CUS + fructooligosaccharide + galactooligosaccharides group vs. CUS group | Faece | C57BL/6 mouse | Down |
| Study M1022 | Type2 | CUS + Tongxieyaofang acidic polysaccharide group vs. CUS group | Faece | C57BL/6 mouse | Down |
| Study M1022 | Type2 | CUS + middle dose of Tongxieyaofang neutral polysaccharide group vs. CUS group | Faece | C57BL/6 mouse | Down |
| Study M1022 | Type2 | CUS + high dose of Tongxieyaofang neutral polysaccharide group vs. CUS group | Faece | C57BL/6 mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Down |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1045 | Type1 | anxiety and depression group vs. control group | Plasma | Human | Down |
| Study M1053 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M1053 | Type2 | CUMS + quercetin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M1056 | Type1 | maternal separation group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Up |
| Study M1103 | Type1 | SLE with depression group vs. control group | Faece | Human | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M117 | Type1 | CVS group vs. control group | Faece | Wistar rat | Up |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M512 | Type1 | CUMS group vs. control group | Urine | Goto-Kakizaki rat | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M582 | Type1 | CUMS group vs. control group | Faece | C57BL/6N mouse | Down |
| Study M582 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | C57BL/6N mouse | Up |
| Study M582 | Type3 | control + fluoxetine group vs. control group | Faece | C57BL/6N mouse | Up |
| Study M604 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M604 | Type2 | CUMS + PBR group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M608 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M608 | Type2 | CUMS + Poria cocos group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M689 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Chaihu group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M743 | Type1 | CUS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M749 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Up |
| Study M858 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M867 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M867 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Plasma | Sprague-Dawley rat | Unknown |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Down |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M936 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M947 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M947 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M964 | Type1 | D-galactose + CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M964 | Type2 | D-galactose + CUMS + imipramine group vs. D-galactose + CUMS group | Faece | Sprague-Dawley rat | Down |